STOCK TITAN

Aquestive Therapeutics officer plans roughly $25.8K sale

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
144

Rhea-AI Filing Summary

Aquestive Therapeutics, Inc. officer Matthew W. Davis filed notice of an intended sale of 7,197 common shares, with an approximate aggregate market value of $25,765.26. The approximate sale date is November 12, 2026. Davis acquired the shares from the issuer as restricted stock units on November 10, 2026. The notice lists May 26, 2026 as the Rule 10b5-1 plan adoption or instruction date and names Morgan Stanley Smith Barney LLC as broker.

Common shares intended for sale 7,197 shares Approximate sale date November 12, 2026
Aggregate market value $25,765.26 Approximate market value of the shares intended for sale
Common shares outstanding 125,687,705 shares Outstanding share count stated in the notice
Restricted Stock Units financial
"The shares were acquired as Restricted Stock Units from the issuer."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Rule 10b5-1 regulatory
"The notice lists a Rule 10b5-1 plan adoption or instruction date."
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
Aggregate Market Value financial
"Approximate aggregate market value of the shares intended for sale."
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AQST shares does officer Matthew W. Davis plan to sell?

Matthew W. Davis, an officer of Aquestive Therapeutics, reported an intended sale of 7,197 common shares, with an approximate aggregate market value of $25,765.26. The notice gives an approximate sale date of November 12, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading